News & Events
Newsletter
Picture Gallery
 
Search On Site
 
   
 
 
 
Home | Media Room >News & Events Details

News & Events Details

Wednesday, December 09, 2015
Valcard Launch December 2015
Efroze has always held a prominent position in its cardiovascular product portfolio segment, striving to serve patients with quality pharmaceuticals for decades. Efroze has now introduced a new anti-hypertensive treatment approach by launching Valcard a combination of Amlodipine & Valsartan, available in 03 different strengths.

Amlodipine is a calcium channel blocker (CCB) and Valsartan an angiotensin II receptor blocker (ARB). Valcard is indicated for the treatment of hypertension, to lower blood pressure:
• In patients not adequately controlled on monotherapy
• As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Valcard is now available in market with three standard strengths:

• Valcard (amlodipine 5mg + Valsartan 80mg)
• Valcard (amlodipine 5mg + Valsartan 160mg)
• Valcard (amlodipine 10mg + Valsartan 160mg)
Back to News List
 
 
 
 
 
 
       
 
Copyright © Efroze Chemical Industries (pvt) Limited. All rights are reserved. Designed by EfroTech